Analysts Set Celcuity Inc. (NASDAQ:CELC) PT at $29.17

Celcuity Inc. (NASDAQ:CELC - Get Free Report) has earned a consensus recommendation of "Buy" from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $29.17.

Several brokerages have recently commented on CELC. Stifel Nicolaus boosted their price objective on Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a report on Monday, October 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $23.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Leerink Partners started coverage on Celcuity in a research note on Monday, July 22nd. They issued an "outperform" rating and a $29.00 target price for the company. Lifesci Capital started coverage on Celcuity in a research note on Monday, August 26th. They issued an "outperform" rating and a $27.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $27.00 target price on shares of Celcuity in a research note on Thursday, August 15th.

Celcuity Price Performance

Shares of NASDAQ CELC traded down $0.36 during midday trading on Thursday, hitting $15.50. 133,500 shares of the company's stock were exchanged, compared to its average volume of 275,968. Celcuity has a 12-month low of $9.91 and a 12-month high of $22.19. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54. The company has a market cap of $544.07 million, a price-to-earnings ratio of -5.58 and a beta of 0.75. The business's fifty day moving average price is $15.44 and its two-hundred day moving average price is $16.18.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same period in the previous year, the business posted ($0.66) EPS. As a group, research analysts forecast that Celcuity will post -2.54 EPS for the current fiscal year.

Institutional Trading of Celcuity

Hedge funds and other institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC bought a new stake in Celcuity in the third quarter valued at approximately $33,000. Values First Advisors Inc. bought a new position in shares of Celcuity during the third quarter valued at approximately $86,000. Quest Partners LLC raised its holdings in shares of Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company's stock valued at $95,000 after acquiring an additional 1,379 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of Celcuity during the third quarter valued at approximately $119,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Celcuity by 78.5% during the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company's stock valued at $193,000 after acquiring an additional 3,930 shares in the last quarter. Institutional investors own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.